ATI Reproductive and Genitourinary
A health care professional is caring for a patient who is about to begin using transdermal testosterone gel (AndroGel) to treat delayed puberty. When talking with the patient, which of the following instructions should the health care professional include? (Select all that apply.) A) Apply the gel to the scrotum. B) Cover the area of application with clothing. C) Wash your hands after applying the gel. D) Do not shower for several hours after applying the gel. E) Apply the gel to the gums above an upper incisor.
ANS: B, C, D
A health care professional administers oxybutynin (Ditropan) to a patient to treat neurogenic bladder. Which of the following assessment findings should the health care professional recognize as an adverse effect? (Select all that apply.) A) Diaphoresis B) Dilated pupils C) Dizziness D) Distended bladder E) Fever
ANS: B, C, D, E
A health care professional is caring for a patient who is about to begin taking conjugated equine estrogen (Premarin). The health care professional should tell the patient to report which of the following indications of a serious adverse reaction? A) Hot flashes B) Urinary tract infection C) Vaginal bleeding D) Bone pain
ANS: C Rationale: Estrogen hormone replacement therapy increases the risk of endometrial cancer. Health care professionals should tell patients using the drugs to report recurrent of persistent vaginal bleeding and pelvic pain.
A health care professional is caring for a patient who is about to begin taking cabergoline to treat infertility. The health care professional should explain to the patient the need to monitor which of the following laboratory tests? A) Potassium B) Glucose C) BUN and creatinine D) Prolactin level
ANS: D Rationale: Cabergoline inhibits the secretion of prolactin. The primary care provider should monitor prolactin levels to determine the appropriate dosage.
A health care professional should question the use of conjugated equine estrogen (Vagifem) by a patient who has a history of which of the following? A) Osteoporosis B) Peptic ulcer disease C) Rheumatoid arthritis D) Blood clots
ANS: D Rationale: Patients who have a history of thromboembolic disease may not use estrogen replacement therapy because of the risk of thrombophlebitis, myocardial infarction, pulmonary embolism, and cerebrovascular accident.
